Cover Image
Market Research Report

Global Atherosclerosis Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 905976
Published Content info 136 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Atherosclerosis Therapeutics Market 2019-2023
Published: August 6, 2019 Content info: 136 Pages
Description

About this market

Atherosclerosis occurs due to the development of plaque inside the artery, which later hardens and becomes thick. This hardened plaque narrows the artery which decreases the blood supply to body parts. Technavio's atherosclerosis therapeutics market analysis considers sales from small molecules and biologics. Our analysis also considers the sales of atherosclerosis therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant share, and this trend is expected to continue over the forecast period. Factors such as the availability of a wide range of drugs for the treatment of atherosclerosis will play a significant role in the small molecule segment to maintain its market position. Also, our global atherosclerosis therapeutics market report also looks at factors such as increased risk factors of atherosclerosis, availability of advanced diagnostic methods and rising prevalence of hypercholesterolemia. However, uncertainties in the side-effects associated with atherosclerosis therapeutics, product recalls, and stringent regulatory environment may hamper the growth of the atherosclerosis therapeutics market over the forecast period.

Overview

Demand for the availability of advanced diagnostic methods

The advanced diagnostic techniques employed for diagnosis of atherosclerosis have undergone significant improvements in terms of technology and high-definition picture quality and provide information about the presence, size, and the composition of the plaque. These advanced diagnostic methods will lead to the expansion of the global atherosclerosis therapeutics market at a CAGR of over 5% during the forecast period.

Rising focus on identification of new drug targets for atherosclerosis

The current research on atherosclerosis focuses on evaluating new drug targets that have genetic and mechanistic links. Efforts in this area have revealed some new pro-atherosclerotic pathways and can significantly reduce the risk of atherosclerosis. Growing R&D effects in this area are expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global atherosclerosis therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global atherosclerosis therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global atherosclerosis therapeutics manufacturers, that include AstraZeneca Plc, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi.

Also, the atherosclerosis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents
Product Code: IRTNTR31817

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Identification of new pathogenic targets
  • Identification of new drug targets for atherosclerosis
  • Strong incidence of coronary heart disease (CHD)

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Hypothesis behind LDL deposition in intima
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Some of the key clinical trials in global atherosclerosis therapeutics market
  • Exhibit 20: Product - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by product
  • Exhibit 22: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by product
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Adoption rate of health insurance coverage among US adults with CHD, or a stroke, or both, 2019
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Incidence rate of CHD in adults aged 45 years and above 2019
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: AstraZeneca Plc - Vendor overview
  • Exhibit 53: AstraZeneca Plc - Business segments
  • Exhibit 54: AstraZeneca Plc - Organizational developments
  • Exhibit 55: AstraZeneca Plc - Geographic focus
  • Exhibit 56: AstraZeneca Plc - Key offerings
  • Exhibit 57: AstraZeneca Plc - Key customers
  • Exhibit 58: Bayer AG - Vendor overview
  • Exhibit 59: Bayer AG - Business segments
  • Exhibit 60: Bayer AG - Organizational developments
  • Exhibit 61: Bayer AG - Geographic focus
  • Exhibit 62: Bayer AG - Segment focus
  • Exhibit 63: Bayer AG - Key offerings
  • Exhibit 64: Bayer AG - Key customers
  • Exhibit 65: Merck & Co. Inc. - Vendor overview
  • Exhibit 66: Merck & Co. Inc. - Business segments
  • Exhibit 67: Merck & Co. Inc. - Organizational developments
  • Exhibit 68: Merck & Co. Inc. - Geographic focus
  • Exhibit 69: Merck & Co. Inc. - Segment focus
  • Exhibit 70: Merck & Co. Inc. - Key offerings
  • Exhibit 71: Merck & Co. Inc. - Key customers
  • Exhibit 72: Novartis AG - Vendor overview
  • Exhibit 73: Novartis AG - Business segments
  • Exhibit 74: Novartis AG - Organizational developments
  • Exhibit 75: Novartis AG - Geographic focus
  • Exhibit 76: Novartis AG - Segment focus
  • Exhibit 77: Novartis AG - Key offerings
  • Exhibit 78: Novartis AG - Key customers
  • Exhibit 79: Sanofi - Vendor overview
  • Exhibit 80: Sanofi - Business segments
  • Exhibit 81: Sanofi - Organizational developments
  • Exhibit 82: Sanofi - Geographic focus
  • Exhibit 83: Sanofi - Segment focus
  • Exhibit 84: Sanofi - Key offerings
  • Exhibit 85: Sanofi - Key customers
  • Exhibit 86: Validation techniques employed for market sizing
  • Exhibit 87: Definition of market positioning of vendors
Back to Top